- Kye Pharmaceuticals has launched Dyanavel XR (amphetamine extended-release) tablets in Canada for treating ADHD in adults and children aged 6-12 years.
- Dyanavel XR is a long-acting psychostimulant and the first and only extended-release amphetamine in Canada that can be chewed or swallowed whole without affecting efficacy, using LiquiXR technology.
- The treatment combines immediate- and extended-release amphetamine particles to provide sustained symptom control throughout the day and is aligned with first-line ADHD treatment recommendations from CADDRA guidelines.
- Kye stated that the launch expands its ADHD portfolio and provides patients and healthcare professionals with an additional evidence-based treatment option for managing ADHD across different age groups.
Takeaways:
Kye Pharmaceuticals’ launch of Dyanavel XR in Canada adds a first-and-only chewable/swallowable extended-release amphetamine for ADHD in adults and children 6–12 years, aligning with CADDRA first-line stimulant recommendations. Its LiquiXR technology combines immediate- and extended-release particles to support full-day symptom control without losing efficacy if chewed, improving flexibility for patients who struggle with swallowing pills.
Source: CA Newswire
